The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC)
targetable by small-molecule inhibitors, and the development of immunotherapies, have …

Rearrangements of the ROS1 gene occur in 1–2 % of non-small cell lung cancers (NSCLCs).
Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the …

For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies
have changed significantly due to the introduction of targeted therapies and immunotherapy. …

We present a series of 16 salivary gland tumors with histomorphologic and
immunohistochemical features reminiscent of secretory carcinoma of the breast. This is a hitherto …

Aldosterone-producing adenomas (APAs) are the commonest curable cause of hypertension.
Most have gain-of-function somatic mutations of ion channels or transporters. Herein we …

PURPOSE Triple-negative breast cancer (TNBC) is considered aggressive, and therefore,
virtually all young patients with TNBC receive (neo) adjuvant chemotherapy. Increased …

A high density of tumor-infiltrating CD8 + T cells and CD20 + B cells correlates with prolonged
survival in patients with a wide variety of human cancers, including high-grade serous …

Tumor-infiltrating leukocytes and other immunohistochemical parameters were evaluated in
pretherapeutic biopsies and resection specimens in 73 patients undergoing neoadjuvant …

The frequency and prognostic relevance of RET proto-oncogene somatic mutations in
sporadic medullary thyroid carcinoma (MTC) remain controversial. In order to study somatic …

Purpose: The successful implementation of immune checkpoint inhibitors (ICI) in the clinical
management of various solid tumors has raised considerable expectations for patients with …